ArticleThe Clinical biochemist. Reviews2004
Lipoprotein(a): biology and clinical importance.
Article in The Clinical biochemist. Reviews, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 62 citations in OpenAlex.
- Effects of mixed nut consumption on LDL cholesterol, lipoprotein(a), and other cardiometabolic risk factors in overweight and obese adults.Nutrition, metabolism, and cardiovascular diseases : NMCD · 2023Trial
- IL-6 blockade by monoclonal antibodies inhibits apolipoprotein (a) expression and lipoprotein (a) synthesis in humans.Journal of lipid research · 2015Trial
- Affinity-Based Isolation and One-Pot Analysis of Extracellular Vesicles from Biofluids Using Phase Separated Zwitterionic Coacervates.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- The Impact of Diet on Lipoprotein(a) Levels.Life (Basel, Switzerland) · 2024Review
- Role of Lipoprotein(a) Reduction in Cardiovascular Disease.Journal of clinical medicine · 2024Review
- Lipoprotein Lipidomics as a Frontier in Non-Alcoholic Fatty Liver Disease Biomarker Discovery.International journal of molecular sciences · 2024Review
- Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Where Do We Stand?International journal of molecular sciences · 2024Review
- Lipoprotein(a): Levels and Reference Intervals Among People in Saudi Arabia.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Article
- The ins and outs of lipoprotein(a) assay methods.Archives of medical sciences. Atherosclerotic diseases · 2023Article
- Role of Lipoproteins in the Pathophysiology of Breast Cancer.Membranes · 2022Review
- Lipoproteins and cancer: The role of HDL-C, LDL-C, and cholesterol-lowering drugs.Biochemical pharmacology · 2022Review
- The Association Between Medication Non-Adherence and Early and Late Readmission Rates for Patients with Acute Coronary Syndrome.International journal of general medicine · 2022Article
- Developing Electron Microscopy Tools for Profiling Plasma Lipoproteins Using Methyl Cellulose Embedment, Machine Learning and Immunodetection of Apolipoprotein B and Apolipoprotein(a).International journal of molecular sciences · 2020Article
- High Lipoprotein(a) Levels as a Predictor of Major Adverse Cardiovascular Events in Hospitalized-Acute Myocardial Infarction Patients.Vascular health and risk management · 2020Article
- Role of lipoprotein (a) in peripheral arterial disease.Annals of translational medicine · 2019Article
- The effect of chronic kidney disease on lipid metabolism.International urology and nephrology · 2019Review
- Article
- Effect of Two Lipoprotein (a)-Associated Genetic Variants on Plasminogen Levels and Fibrinolysis.G3 (Bethesda, Md.) · 2016Article
- Lipoprotein (a): a Unique Independent Risk Factor for Coronary Artery Disease.Indian journal of clinical biochemistry : IJCB · 2016Review
- Low-density lipoprotein cholesterol, apolipoprotein B, and risk of coronary heart disease: from familial hyperlipidemia to genomics.Biological research for nursing · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lipoprotein(a) [Lp(a)] is a unique lipoprotein that has emerged as an independent risk factor for developing vascular disease. Plasma Lp(a) levels above the common cut-off level of 300 mg/L place individuals at risk of developing heart disease particularly if combined with other lipid and thrombogenic risk factors. Studies in humans have shown Lp(a) levels to be hugely variable and under strict genetic control, largely by the apolipoprotein(a) [apo(a)] gene. In general, Lp(a) levels have proven difficult to manipulate, although some factors have been identified that can influence levels. Research has shown that Lp(a) has a high affinity for the arterial wall and displays many athero-thrombogenic properties. While a definite function for Lp(a) has not been identified, the last two decades of research have provided much information on the biology and clinical importance of Lp(a).
Identifiers
18516206PMC1853362W1514463980What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.